Compare SWBI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | ACRS |
|---|---|---|
| Founded | 1852 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.8M | 748.6M |
| IPO Year | 2000 | 2015 |
| Metric | SWBI | ACRS |
|---|---|---|
| Price | $15.01 | $5.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $14.00 | $10.20 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 06-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | 36.67 | ★ 69.01 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $523,845,000.00 | $1,683,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | $4.24 |
| P/E Ratio | $36.24 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $7.73 | $1.46 |
| 52 Week High | $17.56 | $5.85 |
| Indicator | SWBI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 61.86 |
| Support Level | $13.83 | $4.13 |
| Resistance Level | $15.24 | $5.85 |
| Average True Range (ATR) | 0.47 | 0.33 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 13.28 | 73.40 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.